Prof. Dr. rer. nat. Barbara Sickm?ller is a pharmacist. She studied and obtained her doctorate at the Philipps University in Marburg - Germany (1967-1974).

From 1977 she worked as a scientific executive at the Association of the German Pharmaceutical Industry (BPI) and took over the section "Drug Safety" of BPI in 1979. 1984/1985 she had a sabbatical year in the USA with training into US drug legislation. From 1988 she was appointed as head of the department "Medical affairs" and from 1997 Director of the Medicines and Pharmacy Division of BPI. In 2000 she was appointed as Deputy Director General of BPI.

Since 1987 until 2011 she gave yearly lectures in the department of Pharmacy, University of Marburg, and was appointed honorary Professor of the University of Marburg/Lahn (Januar 2000). In addition, she gave lectures for the Master of Drug Regulatory Affairs at the University in Bonn. She had further teaching assignments at the Universities of Frankfurt and Heidelberg on Pharmacovigilance and clinical trials, and has published numerous publications and book contributions in these regulatory areas.

The German Ministry of Health appointed her as Member of the Advisory Committee on prescription of pharmaceutical products, the Commission on Medicines for Children and Adolescents (KAKJ) and member of the Board of Trustees of the Institute for Quality and Efficiency in Health Care (IQWiG) and a member of the Board of Trustees of the German Agency for Health Technology Assessment (HTA) at DIMDI.

She was member of several Working Groups of the Council for International Organizations of Medical Sciences (CIOMS) and the International Council for Harmonization of Marketing Authorization Requirements (ICH) in the areas of pharmacovigilance and clinical trials.

Since March 2012 she has retired and is now active as Senior Scientific Advisor for BPI. Furthermore,she gives lectures on Pharmacovigilance and clinical trials at the Universities in Bonn, Heidelberg and Marburg.

In July 2014 she was appointed President of the German Association for Regulatory Affairs (DGRA)in Bonn and in October 2014 as member of the university council of the University of Applied Sciences of Central Hesse (THM) in Gie?en.

Dr Brigitte Franke-Bray is an Independent Consultant with special expertise in Pharmaceutical Medicine. From September 2018 to March 2023 she was Treasurer and Board Member of IFAPP (ifapp.org) and still is a Board Member of PharmaTrain (pharmatrain.eu) and a member of the Advisory Board of ECPM (ecpm.unibas.ch). She has also been a board member of SGPM (sgpm.ch) for many years and a member of EUPATI (eupati.ch). She worked as a hospital physician in internal medicine, pneumology and allergology in Germany, then joined Ciba-Geigy in 1985 and afterwards Sandoz as a Medical Expert for respiratory diseases. In 1995 she joined Quintiles as Medical Director/Office Head Switzerland became Director DIA (diaglobal.org) Europe, Middle East, Africa, in 2005 and, additionally, the DIA's Global Training Officer. In 2013, she was a Clinical Reviewer at the Swiss Medicines Regulatory Authority Swissmedic in Marketing Authorisation before she became a globally acting Medical Director in the Respiratory Franchise in Novartis Basel, Switzerland, then started her consultancy in Pharmaceutical Medicine in 2018. Dr Franke-Bray has ample experience in Pharmaceutical Medicine education and training, also through the IMI (imi.europa.eu) projects PharmaTrain and EUPATI. She was a teacher and examiner at a diploma course at the University of Basel, Switzerland, and is a regular examiner at Basel University’s ECPM training course and also for the board-certified physicians’ specialisation in Pharmaceutical Medicine in Switzerland.